Bristol Myers Squibb (BMY) Other Non Operating Income (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Other Non Operating Income for 18 consecutive years, with $61.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non Operating Income rose 112.35% year-over-year to $61.0 million in Q2 2026; TTM through Jun 2026 was $188.0 million, a 113.7% increase from a year earlier, with the FY2025 full-year figure at -$997.0 million, down 3.0% from the prior year.
• Other Non Operating Income was $61.0 million for Q2 2026 at Bristol Myers Squibb, up from -$32.0 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $413.0 million in Q1 2023 and troughed at -$649.0 million in Q1 2022.
• A 5-year average of -$53.1 million and a median of $9.5 million in 2025 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income sank 14300.0% in 2022 and jumped 163.64% in 2023, its largest moves.
• Over 5 years, Other Non Operating Income stood at $217.0 million in 2022, then surged by 70.97% to $371.0 million in 2023, then slumped by 182.21% to -$305.0 million in 2024, then surged by 116.72% to $51.0 million in 2025, then gained by 19.61% to $61.0 million in 2026.
• The last three Other Non Operating Income figures came in at $61.0 million (Q2 2026), -$32.0 million (Q1 2026), and $51.0 million (Q4 2025), per Business Quant data.